Remotiv® – Ze 117
Remotiv® – Ze 117
Treatment of mild to moderate depressive episodes.
- Non-inferiority to standard drugs
- recommended “First-line” treatment
- Low drug-drug interaction risk
This is an authorised medicinal product.
Max Zeller Söhne AG, 8590 Romanshorn
Product information
Indication
For the treatment of mild to moderate depressions (WHO ICD10 F32.0/F32.1)
Extract composition
Remotiv 250®: 250 mg of dry extract (Ze 117) from Hypericum perforatum L. herba
Remotiv 500®: 500 mg of dry extract (Ze 117) from Hypericum perforatum L. herba
Drug-extract ratio (DER): 4-7:1
Extraction solvent: 57.9% ethanol (V/V)
Dosage
Remotiv 250®: 2 film-coated tablets per day.
Remotiv 500®: 1 film-coated tablet per day.
Recommended for minimum 6 weeks.
Clinical Evidence & Mode of action
The information contained in this section is intended for healthcare professionals only.
Please click the button below to confirm that you are a healthcare professional.
Get in Touch
Max Zeller Soehne AG Seeblickstr. 4 8590 Romanshorn Switzerland
Ze 117 – The Difference
Effective natural mood enhancer – Comparable efficacy to SSRIs in mild/moderate depression and high responder rates, shown by clinical studies
Triple action – Inhibits presynaptic reuptake of dopamine, serotonin and noradrenaline
First-line therapy – Proposed by doctors in various guidelines as first-line treatment for mild to moderate depression
Excellent safety – Ze 117 is better tolerated than SSRIs and has very low potential for drug-drug interactions due to special extract containing low hyperforin levels (≤1%), suitable for long-term treatment
